Literature DB >> 6207457

Changes in monoamine metabolites measured by simultaneous in vivo differential pulse voltammetry and intracerebral dialysis.

T Sharp, N T Maidment, M P Brazell, T Zetterström, U Ungerstedt, G W Bennett, C A Marsden.   

Abstract

A direct comparison has been made of the drug-induced changes in extracellular levels of 3,4-dihydroxyphenylacetic acid and 5-hydroxyindoleacetic acid measured using intracerebral dialysis and differential pulse voltammetry with carbon fibre electrodes. The comparison was carried out in chloral hydrate anaesthetized rats with a pretreated carbon fibre electrode implanted in one striatum and an intracerebral dialysis loop in the contralateral striatum. 3,4-Dihydroxyphenylacetic acid and 5-hydroxyindoleacetic acid in the dialysis perfusates were assayed by high pressure liquid chromatography with electrochemical detection. d-Amphetamine (2 mg/kg) decreased extracellular 3,4-dihydroxyphenylacetic acid and the height of the 3,4-dihydroxyphenylacetic acid oxidation peak, while haloperidol (0.5 mg/kg) increased 3,4-dihydroxyphenylacetic acid levels measured in the perfusates and the height of the 3,4-dihydroxyphenylacetic acid oxidation peak. In these experiments there were parallel changes in 3,4-dihydroxyphenylacetic acid levels and peak height and a close correlation between these changes. Tranylcypromine (10 mg/kg) produced an almost parallel decrease in extracellular 5-hydroxyindoleacetic acid (dialysis) and the height of the 5-hydroxyindoleacetic acid oxidation peak, with similar percentage changes and good correlation values being obtained. However, while 5-hydroxy-L-tryptophan (25 mg/kg) increased both the 5-hydroxyindoleacetic acid levels and the height of the 5-hydroxyindoleacetic acid oxidation peak, 5-hydroxyindoleacetic acid in the dialysis perfusates showed a greater increase than the oxidation peak. The results show a close correlation between changes in extracellular 3,4-dihydroxyphenylacetic acid and its respective voltammetric peak and strongly support the use of in vivo differential pulse voltammetry for monitoring dopamine metabolism.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6207457     DOI: 10.1016/0306-4522(84)90015-0

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  9 in total

1.  Relationship between extracellular 5-hydroxytryptamine and behaviour following monoamine oxidase inhibition and L-tryptophan.

Authors:  A J Sleight; C A Marsden; K F Martin; M G Palfreyman
Journal:  Br J Pharmacol       Date:  1988-02       Impact factor: 8.739

2.  Proceedings of the British Pharmacological Society. Leeds, 12th-14th July 1989. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

3.  Proceedings of the British Pharmacological Society. University of Southampton, 17th-19th July 1985. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1985-09       Impact factor: 8.739

4.  Proceedings of the British Pharmacological Society. Cardiff, 10th-12th April, 1985. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1985-06       Impact factor: 8.739

5.  Time-course of recovery of dopamine neuron activity during reinnervation of the denervated striatum by fetal mesencephalic grafts as assessed by in vivo voltammetry.

Authors:  C Forni; P Brundin; R E Strecker; S el Ganouni; A Björklund; A Nieoullon
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

6.  Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis.

Authors:  J P Chen; W Paredes; J Li; D Smith; J Lowinson; E L Gardner
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  Muscarinic antagonists attenuate the increase in accumbens and striatum dopamine metabolism produced by clozapine but not by haloperidol.

Authors:  R Rivest; C A Marsden
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

8.  The 5-HT1 receptor agonist RU-24969 decreases 5-hydroxytryptamine (5-HT) release and metabolism in the rat frontal cortex in vitro and in vivo.

Authors:  M P Brazell; C A Marsden; A P Nisbet; C Routledge
Journal:  Br J Pharmacol       Date:  1985-09       Impact factor: 8.739

9.  Microdialysis in the rat striatum: effects of 24 h dexamethasone retrodialysis on evoked dopamine release and penetration injury.

Authors:  Kathryn M Nesbitt; Erika L Varner; Andrea Jaquins-Gerstl; Adrian C Michael
Journal:  ACS Chem Neurosci       Date:  2014-12-22       Impact factor: 4.418

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.